Vincent O. Dezentjé

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 445 citations · Full text

Medicine, Oncology, Breast Oncology +15

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer

Vincent O. Dezentjé, Nico J.C. van Blijderveen, Hans Gelderblom et al. · Journal of Clinical Oncology · 2010 · 162 citations

Medicine, Oncology, Pharmacology +14

Adjuvant chemotherapy in small node-negative triple-negative breast cancer

Tessa G. Steenbruggen, Erik van Werkhoven, Mette S. van Ramshorst et al. · European Journal of Cancer · 2020 · 118 citations · Full text

Medicine, Oncology, Breast Oncology +10

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · European Journal of Cancer · 2018 · 90 citations · Full text

Medicine, Oncology, Pharmacoeconomics +17